Premium
Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt‐1, from a human hematopoietic cell line NALM‐16
Author(s) -
Inoue Toshiya,
Kibata Keiko,
Suzuki Motoyuki,
Nakamura Shuji,
Motoda Ryuichi,
Orita Kunzo
Publication year - 2000
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(00)01246-1
Subject(s) - haematopoiesis , cell culture , hematopoietic growth factor , biology , vascular endothelial growth factor , growth factor , microbiology and biotechnology , western blot , cell growth , northern blot , cancer research , endothelial stem cell , messenger rna , vegf receptors , receptor , gene , stem cell , biochemistry , in vitro , genetics
An antagonistic activity against vascular endothelial growth factor (VEGF) was identified in the culture supernatants of certain human hematopoietic cell lines and the antagonistic protein was purified from NALM‐16 (B cell) culture supernatant. Amino acid sequencing of the N‐terminus and Western blot analysis confirmed that the antagonist was identical to a soluble truncated form of Flt‐1 (sFlt‐1). Seventeen of 52 leukemia and lymphoma cell lines investigated expressed sFlt‐1 mRNA, and 16 of the sFlt‐1 expressing cells also expressed VEGF and membrane‐bound Flt‐1 (mFlt‐1). This report is the first showing that sFlt‐1 can be produced by malignant hematopoietic cells, suggesting that the production of VEGF antagonist by hematopoietic cells may play some role in the regulation of VEGF activity in normal and malignant hematopoietic cell proliferation.